Please login to the form below

Not currently logged in
Email:
Password:

NICE

This page shows the latest NICE news and features for those working in and with pharma, biotech and healthcare.

NICE gives nod to plaque psoriasis drug Kyntheum

NICE gives nod to plaque psoriasis drug Kyntheum

NICE gives nod to plaque psoriasis drug Kyntheum. Says the drug is generally more cost-effective than other available treatments. ... Professor Richard Warren, dermatologist for Salford Royal NHS Foundation Trust, said: “This decision from NICE will be

Latest news

  • NICE backs Roche’s Gazyvaro after initial rejection NICE backs Roche’s Gazyvaro after initial rejection

    NICE backs Roche’ s Gazyvaro after initial rejection. An undisclosed discount swayed the cost-effectiveness body. ... Previously, NICE also cleared Gazyvaro as a routine NHS treatment option for adults with chronic lymphocytic leukaemia (CLL).

  • NICE backs EUSA's RCC treatment Fotivda NICE backs EUSA's RCC treatment Fotivda

    NICE backs EUSA's RCC treatment Fotivda. The UK’s cost-effectiveness watchdog recommends its first-line use. ... EUSA Pharma has won NICE backing for Fotivda (tivozanib) as a first-line treatment for advanced renal cell carcimona (RCC).

  • Roche’s lung drug Esbriet reserved for worse cases, says NICE Roche’s lung drug Esbriet reserved for worse cases, says NICE

    The National Institute for Health and Care Excellence (NICE) is standing by its draft guidance and will not extend the use of Esbriet (pirfenidone), which effectively means IPF patients will have ... Esbriet is approved in Europe for treating mild to

  • EC grants MSD’s Prevymis orphan product designation EC grants MSD’s Prevymis orphan product designation

    Houson continued: “This authorisation brings us a step closer to making letermovir available in the UK and we will continue to work closely with NICE, NHS, SMC and other relevant stakeholders

  • NICE finally starts review of Biogen’s Spinraza for SMA NICE finally starts review of Biogen’s Spinraza for SMA

    NICE finally starts review of Biogen’ s Spinraza for SMA. Will evaluate the treatment based on its Single Technology Appraisal process. ... The National Institute for Health and Care Excellence (NICE) has started its appraisal of Biogen’s Spinraza

More from news
Approximately 336 fully matching, plus 836 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 11 fully matching, plus 93 partially matching documents found.

Latest appointments

More from appointments
Approximately 3 fully matching, plus 14 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 4 fully matching, plus 34 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
CMR

Specialising in medical device market research, our approach is people-centric and we thrive on making connections with clients and research...

Latest intelligence

Finding the patient voice
How patients feel and speak about clinical trials...
Six Factors to Consider When Designing Advisory Boards
...
The good, the bad and the ugly
Tracking the pharmaceutical industry’s 2017 evolution and assessing how things may shape up in 2018 - it’s a trilogy of trends...

Infographics